Recent Progress in the Design, Study, and Development of C-Jun N-terminal Kinase Inhibitors As Anticancer Agents
Overview
Biology
Chemistry
Authors
Affiliations
The c-Jun N-terminal kinase (JNK) family, with its three members JNK1, JNK2, and JNK3, is a subfamily of mitogen-activated protein kinases. Involved in many aspects of cellular processes, JNK has been also associated with pathological states such as neurodegenerative diseases, inflammation, and cancers. In oncology, each isoform plays a distinct role depending on the context of the targeted tissue/organ, the tumor stage, and, most likely, the signaling pathway activated upstream. Consequently, the current challenge in finding new successful anti-JNK therapies is to design isoform-selective inhibitors of the JNKs. In this review, a particular focus is given to the JNK inhibitors that have been developed thus far when examining 3D structures of various JNK-inhibitor complexes. Using current data regarding structure-activity relationships and medicinal chemistry approaches, our objective is to provide a better understanding of the design and development of selective JNK inhibitors in the present and future.
Accelerating CAR-T Cell Therapies with Small-Molecule Inhibitors.
Mestermann K, Garitano-Trojaola A, Hudecek M BioDrugs. 2024; 39(1):33-51.
PMID: 39589646 PMC: 11750903. DOI: 10.1007/s40259-024-00688-9.
Yu Y, Gan W, Xiong J, Li J Heliyon. 2024; 10(17):e37344.
PMID: 39296238 PMC: 11408786. DOI: 10.1016/j.heliyon.2024.e37344.
Devi B, Jangid K, Kumar N, Kumar V, Kumar V Mol Divers. 2024; 28(6):4361-4380.
PMID: 38573427 DOI: 10.1007/s11030-024-10820-0.
Fibroblasts in metastatic lymph nodes confer cisplatin resistance to ESCC tumor cells via PI16.
Liang L, Zhang X, Su X, Zeng T, Suo D, Yun J Oncogenesis. 2023; 12(1):50.
PMID: 37914722 PMC: 10620422. DOI: 10.1038/s41389-023-00495-x.
Yao C, Shen Z, Shen L, Kadier K, Zhao J, Guo Y Pharmaceuticals (Basel). 2023; 16(10).
PMID: 37895928 PMC: 10610115. DOI: 10.3390/ph16101459.